Patent issues in biopharmaceutical industry

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

Patent issues in biopharmaceutical industry

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Vijay Kumar

Scientific Tracks Abstracts: J Bioanal Biomed

Abstract :

Intellectual property law enables and gives proper direction along with the rules that individuals and organizations can use when conducting business and making business plans. Unfortunately, the present state of intellectual property laws around the world has created an environment that imposes timing issues ambiguities that are vexing to decision makers in every industry, including the biomanufacturing industry. In United States, courts have defined a ?Super? enablement standard that patent application must meet in order to mature into valid, issued patents. European and Japanese courts appear to be following the lead of the US, by embracing the ?Super? enablement standard. The timing of intellectual property protection and public notice frequently acts as an impediment to developing global strategy and in making changes in the strategy. This talk describes basic considerations and intellectual property law during development and scaling up biomanufacturing processes, including barrier imposed by the law. This talk also describes intellectual property law tools and strategy for protecting assets of a biomanufacturer engaged in development and scale-up operations.

Google Scholar citation report
Citations: 3099

Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report

Journal of Bioanalysis & Biomedicine peer review process verified at publons

Indexed In

arrow_upward arrow_upward